CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis

[January 17, 2013]

Research and Markets: Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/wpfnbh/afluria_seasonal) has announced the addition of GlobalData's new report "Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis" to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vacines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Afluria is a trivalent, inactivated vaccine designed to immunize recipients against seasonal influenza A and B viruses. Afluria is manufactured from viruses that were grown in chicken eggs, harvested via centrifugation, inactivated with beta-propiolactone, disrupted (i.e., split) with a detergent, prior to purification and suspension in a saline buffer. The vaccine is administered via intramuscular injection, where the viral antigens elicit an immune response that helps protect the recipient against seasonal influenza infection. An increased incidence of febrile seizures in patients less than nine years old was associated with the 2010-2011 formulation, which prompted governing panels to recommend against administering Afluria to young children. Afluria is manufactured by CSL Biotherapies, which has marketing agreements with Merck and Pfizer to distribute the vaccine in the US and UK, respectively.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Afluria including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Afluria for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan, China and India

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Appendix

For more information visit http://www.researchandmarkets.com/research/wpfnbh/afluria_seasonal

Source (News - Alert): GlobalData


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter